World's first generic to leading GnRH analogue with controlled release
Xbrane is pioneering high demand biosimilars.
OUTPERFORMING INDUSTRY STANDARDS BY DEVELOPING BIOSIMILARS WITH NEXT GENERATION TECHNOLOGY
Enabling access to critical medication for life critical diseases
Investors
Latest News
-
Xbrane Biopharma tillkännager resultat från in-vivo studie som påvisar ekvivalent tolerabilitet och farmakokinetisk profil för Xlucane jämfört med Lucentis®
Read more >> -
Xbrane Biopharma announces results of in-vivo study showing equivalent tolerability and pharmacokinetic profile of Xlucane compared to Lucentis®
Read more >> -
Xbrane Biopharma uppdaterar kring produktportföljen med ett nytt fullt strategiskt fokus på biosimilarer
Read more >> -
Xbrane Biopharma announces product portfolio update with a new full strategic focus on biosimilars
Read more >> -
Xbrane Biopharma publicerar kvartalsrapport för april - juni 2018
Read more >>
X
